"Win-win..." Huang Jiacai softly repeated the term, a faint curve appeared at the corner of his mouth, fleeting as it was. He leaned back slightly.
"Mr. Rolf, you are an outstanding strategist. You should clearly understand that K Therapy and X-2 are not just two technologies. They represent an erging new mode of healthcare." Huang Jiacai’s tone remained calm, but each word was as if polished with precision, "This mode is not swayed by the interests of any single country or group. Its core driving force is to alleviate the suffering from diseases that humanity has not yet conquered, it is universal benefit."
He paused for a mont, his gaze sweeping over the aides behind Rolf.
"Therefore, regarding cooperation, Ruixing holds a fundantal stance, which is also the final stance." Huang Jiacai’s voice clearly echoed in the eting Room, "We will not sign exclusive agreents, nor those that lead to the fragntation of the global market, with any single corporation. Whether it be BG or other companies currently sending invitations."
Rolf’s pupils suddenly contracted, and the faces of the aides behind him showed subtle changes. This was not the all-out bargaining they had anticipated, bargaining hard and firm; this was a declaration fundantally upending the rules of the ga.
Huang Jiacai seed oblivious to their reactions and continued: "Regarding K Therapy and X-2 technology, Ruixing will, together with Sanbo Research Institute, soon announce a globally unified frawork for technology licensing and access. This frawork will be based on explicit efficacy data, transparent cost accounting, and most importantly, a tiered, affordable licensing fee and dication pricing policy set according to the GDP per capita and healthcare paynt capacity of different countries and regions."
He leaned forward slightly, and in those calm eyes, a sharp glint finally surfaced: "Our goal is to ensure that these truly effective treatnts reach every patient who needs them as quickly and fairly as possible. Rather than becoming a new tool for a small number of interest groups to reap excess profits and create dical inequality."
He lightly tapped the Desktop with his fingertips, this ti the sound seed to be even heavier.
"Gentlen," Huang Jiacai directed his gaze back onto Rolf’s sowhat stiff face, his tone even carried a hint of regret, "So, what we are discussing today is not whether BG can obtain exclusivity or priority rights, that is impossible. What we can discuss is how BG can beco one of the first or most efficient cooperative promotional partners in so regions within this inclusive global frawork by leveraging your existing channels and capabilities."
Rolf felt his throat dry up, he had envisioned countless difficult negotiation scenarios, tit-for-tat clause tug-of-wars, and was even prepared to concede core interests. But he never expected that Huang Jiacai would directly upend the table and redefine the entire ga.
This was not negotiation; this was notification, a universal ultimatum issued by the tech leader to the old order.
"President Huang..." Rolf struggled to organize his words, "Your vision is indeed grand, but business realities are complex, with various regional regulations, paynt systems, market competition..., and as researchers of new drugs and therapies, what you need is to recoup costs and profit at the fastest speed, and we can help you achieve that."
"You’re right, which is why we need experienced partners like BG to address these complex issues." Huang Jiacai replied, his tone still even, "But the precondition of cooperation is to agree with this basic frawork. Otherwise, Ruixing does not mind relying on itself or seeking other more like-minded partners to gradually advance." He took a glance at the reports on the table, "In terms of ti, we have enough patience."
Huang Jiacai was not simply thinking of earning a quick buck; he intended to utilize BG Group and other giants to reach the world and expand his network globally.
Rolf closed his eyes, now understanding that Huang Jiacai was more shrewd and foresighted than he had imagined; he aid to leverage BG Group’s power to expand a global network, and BG had no choice but to comply.
The initial press conference by Li Gaoyang was just a setup, rely a setup for this broader plan. Now BG Group is caught in a dilemma, as cooperation would an making a wedding dress for others, while refusing cooperation would an other multinational corporations will step up, leaving BG Group at a disadvantage in this new field.
A few seconds later, Rolf opened his eyes, now filled only with calm determination after a decision. "I need to communicate with Mr. Li Gaoyang and the board."
"Please do." Huang Jiacai said unhurriedly, "However, several companies are expected to arrive tomorrow, and the evaluation window period we provide to all potential partners is limited. I hope your sincerity does not go to waste."
"Understood!" Rolf’s forehead was covered with fine beads of sweat; many plans he prepared before the negotiation turned out to be unusable, as Huang Jiacai didn’t follow the set routine at all.
The negotiation was suspended, as Rolf hurriedly left with his team, their backs sowhat rushed.
Huang Jiacai remained in the eting Room alone, picking up the invitation letters from several other major giants, glanced at them, and placed them aside casually.
...
The eting Room of Sanbo Research Institute.
On the huge high-definition electronic screen, the real-ti three-dinsional image of Li Gaoyang was slowly rotating, woven into a complex and precise life atlas by nurous translucent bands representing nerve bundles, blood vessel networks, and lymphatic circulation. The image zood in and finally focused on the brain’s deep part, the brainstem, and surrounding area.
Yang Ping stood in front of the screen, frowning slightly. Wearing custom glasses, he moved his fingers in the air, manipulating the image for layer-by-layer peeling, staining, and highlighting markers, using the three-dinsional virtual reality images constructed by Nandu University dical Digital dical Laboratory.
"Here," his finger stopped at an anomalous signal behind the brainstem that almost fused with normal tissue, "The recurrent tumor forms extensive adhesions with the surroundings and shows obvious invasive growth, making surgery unsuitable. He missed the best surgical opportunity, and now K Therapy is the only option. But whether K Therapy is effective for this tumor is unknown, although it might be tried, there are many obstacles to utilizing K Therapy."
His voice was exceptionally clear, with Song Zimo, Xu Zhiliang, and others watching intently. John Ansen, as the chief expert of Li Gaoyang’s dical advisory group, also attended the case discussion.
Obstacles?
John Ansen knew that since Professor Yang said surgery was impossible, there was no doctor in the world capable of performing such surgery. But where were the obstacles Professor Yang ntioned?
"What are these obstacles?" John Ansen asked directly.
Song Zimo continued after Yang Ping’s words to explain: "Our K Therapy is currently not on the market; according to our experint rules, clinical trial approval in the respective country is required before we can accept citizens from that country as volunteers. We had painful lessons regarding such international clinical trials before. We once accepted a patient from the United Kingdom as a clinical volunteer. Although he agreed, various reasons later led to a strong negative social backlash in Europe, and even his family beca one of the promoters of this negative opinion. Hence, we beca more cautious in clinical trials and established new rules that require clinical trial approval from the country before its citizens can beco volunteers."
John Ansen knew about the previous incident, and the backlash’s reverse effect had now hit Li Gaoyang; in reality, Li Gaoyang was one of the promoters of the negative opinion back then.
If so, Li Gaoyang might not be able to accept K Therapy because the heavy resistance prevented K Therapy from ever getting clinical trial approval in the United States.
No surgery, no K Therapy, ans there is no way.
For a mont, John Ansen didn’t know what to say. Having them alter the experint rules was impossible! Since Dr. Song just stated that these rules are protective rules established through painful lessons, they won’t change for anyone, especially not for Li Gaoyang.
It seems they can only work on promoting K Therapy’s approval for clinical trials in the United States.
With the Li Gaoyang family’s power, pushing for K Therapy’s clinical trial approval in the United States is not a difficult task, John Ansen thought.
User Comments
0 comments from readers